Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review

Executive Summary

Despite suffering a setback at the hands of NICE, AstraZeneca's ambitious plans for Lynparza have been boosted by the FDA agreeing to speed up a review of the recent SOLO-1 data which took ESMO by storm last month.

Advertisement

Related Content

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza
Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space
GSK Embraces PARP Promise With Tesaro Buy
AstraZeneca Q3 Sales Rise 'Is Milestone', CEO Soriot 'Not Leaving'
How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124155

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel